HIV
M-A | Worldwide occurrence of HIV-associated neurocognitive disorders and its associated factors.
22 Jul, 2022 | 11:30h | UTC
WHO Guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia.
5 Jul, 2022 | 12:22h | UTCWHO Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.
5 Jul, 2022 | 12:23h | UTCRCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.
21 Jun, 2022 | 11:11h | UTCOriginal Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/NEJM/status/1537185690961686528
M-A: Benefits and risks of rapid initiation of antiretroviral therapy in patients with HIV.
21 Jun, 2022 | 10:41h | UTC
The global landscape of the burden of depressive symptoms/major depression in individuals living with HIV/AIDs and its effect on antiretroviral medication adherence.
10 Jun, 2022 | 10:31h | UTC
Combination anti-HIV antibody infusions suppress virus for prolonged period.
7 Jun, 2022 | 11:45h | UTCNews Release: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health
Original Study: Combination anti-HIV antibodies provide sustained virological suppression – Nature
Commentaries on Twitter
Still don't get the enthusiasm for HIV Rx with bNAbs.
Compared to existing antivirals, they have:
– more baseline resistance
– the need to scale up new resistance tests
– more resource requirements (IV administration)
– … and, if like other monoclonals, $$$
What am I missing? https://t.co/7WZmIjutwE— Paul Sax (@PaulSaxMD) June 1, 2022
This is a wonderful advance.
"Our data demonstrate that combination therapy with broadly neutralizing monoclonal antibodies can provide long-term virological suppression without antiretroviral therapy in individuals with HIV"https://t.co/DKNVSlg3mC
— Michael Worobey (@MichaelWorobey) June 2, 2022
Guidelines for the Kaposi Sarcoma.
6 Jun, 2022 | 11:20h | UTCS1 Guidelines for the Kaposi Sarcoma – Journal of the German Society of Dermatology
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
16 May, 2022 | 01:41h | UTC
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.
13 May, 2022 | 11:28h | UTCInvited Commentary: A collision of pandemics: HIV and COVID-19 – The Lancet HIV
Commentaries on Twitter
New: Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 by Silvia Bertagnolio and colleagues https://t.co/hAyuWi7fMN #openaccess pic.twitter.com/VmjeYMLPHu
— The Lancet HIV (@TheLancetHIV) May 11, 2022
Clinical features of, and risk factors for, severe or fatal COVID-19 among PLWH admitted to hospital…. https://t.co/KKVKwroy4Z Compared with individuals without HIV, PLWH (96% living in Africa) had 15% ⬆️ odds of severe COVID-19 and were 38% more likely to die in hospital.
— Carlos del Rio (@CarlosdelRio7) May 12, 2022
Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection.
12 May, 2022 | 10:20h | UTCCapsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Lenacapavir for HIV Infection in a Multidrug-Resistant Study Cohort – ContagionLive
M-A: Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills.
12 May, 2022 | 08:04h | UTC
Review: Hemophagocytic Lymphohistiocytosis in patients with HIV.
11 May, 2022 | 10:47h | UTCA Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases
M-A: Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy.
1 May, 2022 | 23:09h | UTC
Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.
22 Apr, 2022 | 09:21h | UTCInvited Commentary: Game-changing study of second-line HIV treatment – The Lancet HIV (free registration required)
Original Study: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine
Commentary on Twitter
Efficacy and safety of DTG or DRV in combination with 3TC + ZDV or TDF for second-line treatment of HIV infection (NADIA)… https://t.co/XajA2rLzsp DTG & DRV-based ART maintain good viral suppression during 96 wks; DTG non-inferior to DRV but ⬆️risk of resistance in 2rd-line Rx.
— Carlos del Rio (@CarlosdelRio7) April 21, 2022
[News release – not published yet] New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV.
21 Apr, 2022 | 10:28h | UTCRelated Study: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)
A preliminary study showed prolonged viral suppression is feasible with anti-HIV-1 antibody therapy.
18 Apr, 2022 | 10:06h | UTCProlonged viral suppression with anti-HIV-1 antibody therapy – Nature
Commentary on Twitter
Still in disbelief but our paper is now out in @nature!
We show that immunotherapy with two broadly neutralizing anti-HIV-1 antibodies maintains virologic suppression for several months in people living with HIV in the absence of anti-retroviral therapy.https://t.co/eVem5yDE0C
— Christian Gaebler (@c_gaebler) April 14, 2022
M-A: Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV.
13 Apr, 2022 | 10:18h | UTCNews Release: Protease inhibitors safer than thought for pregnant women with HIV – University of Oxford
RCT: For adults with HIV, a 4-days-on and 3-days-off treatment strategy is noninferior to standard treatment for maintaining viral suppression.
11 Apr, 2022 | 01:56h | UTCA 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)
Commentary: Intermittent Treatment Strategy Is Effective for HIV – Consultant360
Commentaries on Twitter
New: A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Roland Landman and colleagues https://t.co/Tc2Rbo1ISt pic.twitter.com/YTV3XwfELo
— The Lancet HIV (@TheLancetHIV) February 3, 2022
In virologically suppressed people with HIV, randomization to intermittent ART (4 days on, 3 off) was non-inf. to daily dosing. Challenges what I thought about level of adherence needed. Is good adherence only needed during the viremic phase? https://t.co/lM8QZW0C9h
— David Serota (@serotavirus) March 16, 2022
RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.
6 Apr, 2022 | 10:51h | UTCCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Related:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
Systematic Review: Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status.
28 Mar, 2022 | 08:54h | UTC
First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022.
28 Mar, 2022 | 08:46h | UTC
M-A: Tuberculosis screening among HIV-positive inpatients.
25 Mar, 2022 | 08:35h | UTC
Commentary on Twitter
https://twitter.com/CarlosdelRio7/status/1506893108864335872
RCT: Single-dose Liposomal Amphotericin B treatment for Cryptococcal Meningitis.
24 Mar, 2022 | 09:56h | UTCSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Cryptococcal meningitis is a major complication of HIV infection. Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment and was associated with fewer adverse events. https://t.co/cg9DqSDhyN pic.twitter.com/SrKx4tDaph
— NEJM (@NEJM) March 23, 2022
Systematic Review: Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities.
14 Mar, 2022 | 01:19h | UTC